Log in with your email address username.


[Comment] Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma

Immune checkpoint blockade has altered the treatment landscape for many cancers. In the first wave of immunotherapy approvals, studies showed that patients with highly immunogenic tumours such as malignant melanoma gained substantial survival benefits from treatment with anti-CTLA-4 or anti-PD-1 antibodies.1,2 These early wins have given way to mixed evidence for immunotherapy for tumours on the margin of immune exclusion, such as gastro-oesophageal adenocarcinoma. Anti-PD-1 therapy has been shown to be associated with modest response rates and an improvement in overall survival in chemorefractory gastro-oesophageal cancer.